Clinical Trial Update: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and tolerability study of the monoclonal antibody CT-011 in patients with hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CT-011

Snippet

Sponsor: CureTech Ltd | Conditions: Primary Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: TERMINATED